Register for FREE Online Membership6:27 AM Los Angeles | 9:26 AM New York | 2:26 PM London | Sunday, July 6th, 2008 - 10:26 PM Seoul
EQUITIES Magazine Established in 1951  

NexMed, Inc. (NASDAQ: NEXM)

NexMed, Inc. - Medicines of the Future

NexMed Announces Patient Dosing in Phase 3 Program for Anti-Fungal Product

AST WINDSOR, NJ--Jan 31, 2007 - NexMed, Inc. (NASDAQ: NEXM), a developer of innovative transdermal treatments based on the NexACT® drug delivery technology, today announced that its collaborator, Novartis, has commenced dosing of patients in the Phase 3 clinical trials for NM100060, a topical treatment for onychomycosis (nail fungus). NexMed signed an exclusive, worldwide licensing agreement with Novartis in September 2005, under which Novartis has assumed all clinical development, regulatory, manufacturing and commercialization responsibilities for NM100060.

The Phase 3 program for NM100060 consists of two pivotal, randomized, double-blind, placebo-controlled studies. The parallel group studies are designed to assess the efficacy, safety and tolerability of NM100060 in patients with mild to moderate toenail onychomycosis. Approximately 1,000 patients will participate in the two studies, which will take place in the U.S., Europe, Canada and Iceland.

Contact NexMed, Inc.

Mark Westgate
Chief Financial Officer
mwestgate@nexmed.com
NexMed, Inc.

Paula Schwartz
Rx Communications Group, LLC
pschwartz@rxir.com

EQUITIES Subscription





Fidelity Investments

Hard Assets



MoneyShow.com



Investor Relations Group





investools